停用复方新诺明预防治疗对乌干达HIV感染者微生物易位和炎症标志物的影响:COSTOP试验免疫学子研究
停用者炎症标志物CRP和IL-6显著升高,但微生物易位标志物无显著变化,提示复方新诺明的免疫益处可能不主要通过减少微生物易位介导。
要点
- 停用复方新诺明预防治疗1年后,CRP和IL-6显著升高。
- 微生物易位标志物(LPS、IFABP、sCD14)无显著变化。
- 复方新诺明的免疫益处可能不依赖减少微生物易位。
核心结论
- 停用复方新诺明预防治疗未显著改变微生物易位标志物,但炎症标志物CRP和IL-6显著升高。
主要发现
- 停用复方新诺明后,微生物易位标志物LPS、IFABP、sCD14和T细胞活化无显著变化,但EndoCAb IgM降低。
- 与继续治疗组相比,停用组炎症标志物CRP和IL-6显著升高。
临床怎么用
- 在资源有限地区,稳定接受抗逆转录病毒治疗的HIV感染者停用复方新诺明预防治疗可能导致炎症标志物升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health Organization-recommended standard of care in resource-limited settings, but the mechanism of CPT's beneficial effects is unclear. The COSTOP trial (ISRCTN44723643) evaluated the noninferiority of discontinuing CPT in stabilized patients on antiretroviral therapy. The COSTOP immunology substudy was conducted on a subset of COSTOP participants randomized to continue CPT (n = 86) or discontinue CPT (placebo, n = 86) as daily treatment for 1 year. METHODS: We evaluated whether CPT reduces microbial translocation, indicated by the presence of bacterial lipopolysaccharide (LPS) and LPS control factors such as soluble CD14 (sCD14) and endotoxin core antibody (EndoCAb immunoglobulin M [IgM]) in plasma. Intestinal barrier damage as indicated by plasma intestinal fatty acid binding protein (IFABP), T-cell activation, and the inflammatory markers C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) were also evaluated. RESULTS: We found no significant change in markers of microbial translocation (LPS, IFABP, sCD14, and T-cell activation), with decreased EndoCAb IgM. There was significant increase in inflammation markers (CRP and IL-6) after stopping CPT compared to those who continued CPT. CONCLUSIONS: These results add to the evidence of immunological benefits of CPT among HIV-infected populations in resource-limited settings. However, no evidence of reducing microbial translocation was observed.
引用
- Kyosiimire-Lugemwa J, Anywaine Z, Abaasa A, et al. Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy. J Infect Dis. 2020. PMID: 31714954. doi:10.1093/infdis/jiz494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。